Analyst Rating Update on Sequenom (SQNM)

Sequenom (SQNM) : The consensus on Sequenom (SQNM) based on 4 analyst recommendation on the company stock is 3, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Sequenom (SQNM) : Currently there are 3 street experts covering Sequenom (SQNM) stock. The most bullish and bearish price target for the stock is $2 and $1 respectively for the short term. The average price target of all the analysts comes to $1.18. The estimated standard deviation from the target is $0.63.

Company shares have received an average consensus rating of Hold for the current week


Sequenom (NASDAQ:SQNM): The stock was completely flat for the day, closing at $2.36 on Wednesday. The flat closing masks the intraday volatility in the stock. After opening at $2.36, the stock touched an intraday high of $2.38 and a low of $2.36. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $2.36. The total trading volume on Wednesday was 3,598,922.

Sequenom, Inc. (Sequenom) is a life sciences company. The Company serves patients and physicians by providing early patient management information. Its testing focus is principally in prenatal health that includes molecular-based laboratory developed tests (LDTs). The Companys diagnostic services are provided through its wholly owned subsidiary, Sequenom Laboratories. Sequenom Laboratories develops and validates its tests for use in, and by Sequenom Laboratories, as a testing service to physicians. Sequenom Laboratories is primarily focused on expanding the commercial use of, and reimbursement for its prenatal LDTs, and developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF LDT, SensiGene RhD LDT, VisibiliT LDT and Test Send-out Agreements.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.